Ten post jest także dostępny w języku: polski
Invention Med, a Polish technology company specializing in virtual and augmented reality solutions, has ambitious development plans for the coming years. The company plans to build, among others, the Centre for Innovative Medical Simulations in Bydgoszcz. It also wants to develop a virtual syringe. Additionally, Invention Med hopes to be switched to the Warsaw Stock Exchange in the coming months.
Europe’s first Centre for Innovative Medical Simulations
The main investment objective of Invention Med is the Centre for Innovative Medical Simulations for virtual (VR) and augmented (AR) reality. The facility will be built in Bydgoszcz and will enable the simulation of treatments with many specialisations. First of all, simulations will be possible for cardiology and cardiosurgery. However, the company counts on development in such areas as neurology, geriatrics or surgery. Ultimately, the whole virtual hospital may be built.
The cost of the investment is PLN 30 million. Invention Med counts on PLN 16 million of co-financing for this purpose from the Ministry of Investment and Development, especially since, as the company stresses, it will be the first such centre not only in Poland, but also in Europe.
Virtual syringe for dermatology
In the near future, Invention Med will also develop a virtual syringe project. It will be a company’s medical simulator in virtual reality, which will serve to educate specialists in clinical and aesthetic dermatology. This is the second project of the company in this scope. The first one is TutorDerm – a dermatological treatment simulator, which has already been launched on the market. It can be used, among others, to simulate laser therapy of hemangioma.
The virtual syringe, on the other hand, is supposed to enable the exercises of subcutaneous injections. Both tools will be compatible with each other and create an integral system.
Financing from the WSE and China
In the next few months, Invention Med is counting on the transition from NewConnect to the WSE. The company is also conducting advanced talks with the Hong Kong Kam Fung Group in the area of cooperation. The countries of Asia and the Pacific are the region where the most aesthetic medicine and plastic surgery treatments are performed in the world. The company is also preparing to conclude an agreement with a leading international corporation in the dermatology industry. It will concern the production and commercialisation of a virtual syringe.